ARCHIVES

Drug Development: FDA Grants Breakthrough Therapy Designation to CTL019 In ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 28 | July 11, 2014

Download PDF Visit The Full Archive

Related Articles

NCCS Urges FDA To Finalize Regulations On Expanded Access.

December 19, 2008

NSABP Executive Committee Is Seeking Applications From Surgeons to Lead Group

July 29, 1994

Smokers’ Quitlines Work, California Study Finds

October 25, 2002

ImClone: Waksals To Pay $5 Million To Settle With SEC.

January 28, 2005

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

December 30, 2011

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002